News
Media
All VideosMedical World NewsPodcastsWeekly RecapCure ConnectionsInsightsSpecial ReportNeurologyLive Peer ExchangeClinical Forum InsightsMedcastPeers & PerspectivesRoundtable DiscussionsShows & Podcasts
Conferences
Conference CoverageConference Listing
CME/CE
More
Partners
Publications
NeurologyLiveBridging the GapsInternational Journal of MS Care
Resources
Expert AuthorsFDA NewsFeaturesFellows' CornerFuture Leaders in NeurologyGiants of Multiple SclerosisInteractive ToolsJob BoardLive EventsNeurology ResourcesSponsoredVirtual Events

Subscribe

  • News
  • Media
  • Conferences
  • CME/CE
  • Partners
  • Publications
  • Resources
  • Subscribe
  • Dementia and Alzheimer Disease
  • Epilepsy
  • Genetic Disorders
  • Headache and Migraine
    • Migraine
  • MS and Demyelinating Disorders
    • NMOSD
    • Multiple Sclerosis
  • Movement Disorders
    • Parkinson Disease
    • Dyskinesia
  • Neuromuscular
    • Chronic Inflammatory Demyelinating Polyneuropathy
    • Muscular Dystrophy
    • Ataxia
  • Rare Diseases
  • Sleep Disorders
    • Narcolepsy
    • Excessive Daytime Sleepiness
    • Insomnia
  • Stroke
Spotlight -
Expert Authors|
FDA News|
Upcoming Live Events|
AANEM 2025|
AES 2025|
NSGC 2025
Advertisement

Mary Curry, ND

Advertisement

Articles by Mary Curry, ND

Spinal Muscular Atrophy and COVID-19: Guidance and Resources for Providers

ByMary Curry, ND,Lisa Belter, MPH,Abigail Paras, BS,Leslie Humbel, BA,Jill Jarecki, PhD,Mary Schroth, MD, FAAP, FCCP
August 13th 2020

Advocacy organization Cure SMA provides guidance for health care providers caring for patients with SMA during the ongoing COVID-19 pandemic.

Advertisement

Latest Updated Articles

  • Spinal Muscular Atrophy and COVID-19: Guidance and Resources for Providers
    Spinal Muscular Atrophy and COVID-19: Guidance and Resources for Providers

    Published: August 13th 2020 | Updated:



Advertisement
Advertisement

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

1

Anti-IL6R Therapy Effective in Reducing NMOSD and MOGAD Disease Activity

2

Taysha Doses First Patient in Pivotal Trial for Rett Syndrome Gene Therapy TSHA-102, Aligns With FDA on BLA Plans

3

VMAT2 Inhibitor NBI-1065890 Heads to Phase 2 Study in Tardive Dyskinesia

4

Phase 3 EMBARK Data Released, CTE Associated with Dementia Risk, Pilavapadin Heads to Phase 3 Pain Studies

5

Ocugen’s Stargardt Gene Therapy OCU410ST Provides +6-Letter Gain in BCVA-Evaluable Patients in Phase 1 Trial

  • About Us
  • Advisory Board
  • Editorial
  • Contact Us
  • Advertise
  • Contact MJH LS
  • Do Not Sell My Information
  • Terms and Conditions
  • Privacy
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

  • Contagion Live
  • CGT Live
  • Neurology Live
  • HCP Live
  • Oncology Live
  • Contemporary Pediatrics
  • Contemporary OBGYN
  • Urology Times
  • The Educated Patient
HCP Live
Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us